Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paliperidone

FDA-approved product (tablet, extended release, oral), marketed as Invega, Paliperidone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paliperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paliperidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paliperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Bioequivalence Study of PP3M in Patients With Schizophrenia

    NCT07493551 · start 2024-10-09

    Registered record
    Registry ID
    NCT07493551
    Conditions
    Schizophrenia
    Interventions
    Paliperidone Palmitate Injection (3M)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-10-09
    Completion
    2026-12-31
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone Palmitate Injection (3M)
    PhaseNot applicable
    Registry statusRecruiting

  • Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

    NCT06060886 · start 2023-11-01

    Registered record
    Registry ID
    NCT06060886
    Conditions
    Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis
    Interventions
    Aripiprazole; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-11-01
    Completion
    2025-12-31
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders +3 more
    InterventionAripiprazole; Paliperidone
    PhasePhase 4
    Registry statusUnknown

  • Relative Bioavailability of LY03010 Compared to Listed Drug

    NCT04922593 · start 2021-01-13

    Registered record
    Registry ID
    NCT04922593
    Conditions
    Schizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia Spectrum; Mental Disorders; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Psychotropic Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action
    Interventions
    LY03010; paliperidone palmitate; INVEGA SUSTENNA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-13
    Completion
    2022-04-15
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia Spectrum +8 more
    InterventionLY03010; paliperidone palmitate; INVEGA SUSTENNA
    PhasePhase 1
    Registry statusCompleted

  • Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

    NCT04572685 · start 2020-01-22

    Registered record
    Registry ID
    NCT04572685
    Conditions
    Schizophrenia Patients
    Interventions
    Paliperidone Palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-22
    Completion
    2020-08-20
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia Patients
    InterventionPaliperidone Palmitate
    PhasePhase 1
    Registry statusCompleted

  • A Study of Paliperidone Palmitate 6-Month Formulation

    NCT04072575 · start 2019-09-19

    Registered record
    Registry ID
    NCT04072575
    Conditions
    Schizophrenia
    Interventions
    PP6M injection Dose 1; PP6M injection Dose 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-19
    Completion
    2022-05-03
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPP6M injection Dose 1; PP6M injection Dose 2
    PhasePhase 3
    Registry statusCompleted

  • Substance Misuse To Psychosis for Stimulants

    NCT03485417 · start 2019-06-01

    Registered record
    Registry ID
    NCT03485417
    Conditions
    Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis); Schizophrenia and Related Disorders; Stimulant Dependence; Stimulant Abuse; Pharmacotherapy
    Interventions
    Aripiprazole; Paliperidone; Treatment as Usual
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-06-01
    Completion
    2025-05-31
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis); Schizophrenia and Related Disorders; Stimulant Dependence; Stimulant Abuse +1 more
    InterventionAripiprazole; Paliperidone; Treatment as Usual
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

    NCT03713658 · start 2018-10-18

    Registered record
    Registry ID
    NCT03713658
    Conditions
    Schizophrenia
    Interventions
    Risperidone 3 mg; Paliperidone Palmitate 50 mg eq.; Paliperidone Palmitate 75 mg eq.; Paliperidone Palmitate 100 mg eq.; Paliperidone Palmitate 150 mg eq.; Paliperidone Palmitate 175 mg eq.; Paliperidone Palmitate 263 mg eq.; Paliperidone Palmitate 350 mg eq.; Paliperidone Palmitate 525 mg eq.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-10-18
    Completion
    2019-12-02
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone 3 mg; Paliperidone Palmitate 50 mg eq.; Paliperidone Palmitate 75 mg eq.; Paliperidone Palmitate 100 mg eq. +5 more
    PhasePhase 4
    Registry statusCompleted

  • A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

    NCT03666715 · start 2018-08-07

    Registered record
    Registry ID
    NCT03666715
    Conditions
    Schizophrenia
    Interventions
    Oral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-08-07
    Completion
    2021-05-31
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Paliperidone Palmitate 6-Month Formulation

    NCT03345342 · start 2017-11-20

    Registered record
    Registry ID
    NCT03345342
    Conditions
    Schizophrenia
    Interventions
    PP6M; PP3M 350 mg eq.; PP3M 525 mg eq.; PP1M; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-20
    Completion
    2020-05-08
    Enrolment
    841

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPP6M; PP3M 350 mg eq.; PP3M 525 mg eq.; PP1M +1 more
    PhasePhase 3
    Registry statusCompleted

  • The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia

    NCT03080194 · start 2017-04

    Registered record
    Registry ID
    NCT03080194
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate; control group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-04
    Completion
    2018-04
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate; control group
    PhasePhase 4
    Registry statusUnknown

  • Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

    NCT02472652 · start 2015-06

    Registered record
    Registry ID
    NCT02472652
    Conditions
    Sexual Dysfunction
    Interventions
    Abilify Maintena
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-06
    Completion
    2017-03-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexual Dysfunction
    InterventionAbilify Maintena
    PhasePhase 4
    Registry statusTerminated

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

    NCT02085447 · start 2014-05

    Registered record
    Registry ID
    NCT02085447
    Conditions
    Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Medication Adherence; Medication Non-Adherence
    Interventions
    CAE-L
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Schizophrenia; Schizoaffective Disorder; Medication Adherence +1 more
    InterventionCAE-L
    PhaseNot applicable
    Registry statusCompleted

  • Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

    NCT01584466 · start 2014-01

    Registered record
    Registry ID
    NCT01584466
    Conditions
    Schizophrenia
    Interventions
    Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2014-01
    Completion
    2014-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone
    PhaseNot applicable
    Registry statusWithdrawn

  • An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    NCT01498770 · start 2013-04-01

    Registered record
    Registry ID
    NCT01498770
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Aripiprazole; Quetiapine; Risperidone; Olanzapine; Ziprasidone; Iloperidone; Paliperidone; Lurasidone; Clozapine; Amisulpride; Sertindole; Zotepine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04-01
    Completion
    2017-12-21
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Aripiprazole; Quetiapine; Risperidone +9 more
    PhaseNot recorded
    Registry statusCompleted